L. R. Franca

Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.

G. Lip, J. Healey, H. Diener, 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program

K. Rothman, J. Halperin, S. Dubner, 2022, PloS one.

Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program.

G. Lip, H. Diener, K. Rothman, 2018, The American journal of medicine.

Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program.

G. Lip, G. Boriani, M. Huisman, 2020, European journal of internal medicine.

Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF

H. Diener, K. Rothman, J. Halperin, 2021, TH Open.

Heavy episodic drinking and alcohol consumption in French colleges: the role of perceived social norms.

B. Dautzenberg, M. Reynaud, L. R. Franca, 2010, Alcoholism, clinical and experimental research.

Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis.

R. Launois, N. Saidenberg-Kermanac’h, M. Boissier, 2008, Joint, bone, spine : revue du rhumatisme.

Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records

K. Huybrechts, S. Schneeweiss, J. Franklin, 2018, Clinical pharmacology and therapeutics.

Preliminary study on the role of alternative educational pathways in promoting the use of problem-focused coping strategies

Christophe Genolini, J. Guelfi, C. Genolini, 2009 .

Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program

P. Kermer, D. Lane, P. Reilly, 2019, Thrombosis and Haemostasis.

Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry.

G. Lip, H. Diener, K. Rothman, 2019, The American journal of cardiology.

Contribution of modeling approaches and virtual populations in transposing the results of clinical trials into real life and in enlightening public health decisions.

G. Berdeaux, F. Gueyffier, P. Blin, 2012, Therapie.

USE OF THE PROPENSITY SCORE METHOD FOR RECRUITMENT BIAS REDUCTION IN OBSERVATIONAL STUDIES

R. Launois, K. Lay, S. Payet, 2005 .

Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation

S. Haertter, L. R. França, F. Huang, 2017, Canadian Medical Association Journal.

Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage.

D. Singer, J. Goldstein, S. Regan, 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up

A. Brandes, H. Diener, K. Rothman, 2020, Journal of clinical medicine.

Cost-effectiveness of activated protein C in real-life clinical practice

D. Annane, J. Dhainaut, B. Guidet, 2007, Critical care.